Supplementary materials: Cost-utility of real-time continuous glucose monitoring versus self-monitoring of bloodglucose in people with insulin-treated Type II diabetes in France

These are peer-reviewed supplementary tables for the article 'Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France' published in the Journal of Comparative Effectiveness Research.Supplemental Table S1: Utility and disutility values for events/states.Supplemental Table S2: Costs per diabetes complication or event.Supplemental Table S3: Annual treatment and device costs.Supplemental Table S4: Projected diabetes complications for rt-CGM versus SMBGReferences: References for online-only supplementary material.Aim: Clinical trials and real-world data for Type II diabetes both show that glycated hemoglobin (HbA1c)levels and hypoglycemia occurrence can be reduced by real-time continuous glucose monitoring (rt-CGM)versus self-monitoring of blood glucose (SMBG). The present cost-utility study investigated the long-termhealth economic outcomes associated with using rt-CGM versus SMBG in people with insulin-treated TypeII diabetes in France. Materials & methods: Effectiveness data were obtained from a real-world study,which showed rt-CGM reduced HbA1c by 0.56% (6.1 mmol/mol) versus sustained SMBG. Analyses wereconducted using the IQVIA Core Diabetes Model. A French payer perspective was adopted over a lifetimehorizon for a cohort aged 64.5 years with baseline HbA1c of 8.3% (67 mmol/mol). A willingness-to-paythreshold of €147,093 was used, and future costs and outcomes were discounted at 4% annually. Results:The analysis projected quality-adjusted life expectancy was 8.50 quality-adjusted life years (QALYs) for rt-CGM versus 8.03 QALYs for SMBG (difference: 0.47 QALYs), while total mean lifetime costs were €93,978for rt-CGM versus €82,834 for SMBG (difference: €11,144). This yielded an incremental cost-utility ratio(ICUR) of €23,772 per QALY gained for rt-CGM versus SMBG. Results were particularly sensitive to changesin the treatment effect (i.e., change in HbA1c), annual price and quality of life benefit associated withrt-CGM, SMBG frequency, baseline patient age and complication costs. Conclusion: The use of rt-CGM islikely to be cost-effective versus SMBG for people with insulin-treated Type II diabetes in France.

本数据集为发表于《比较有效性研究杂志》上的文章《法国胰岛素治疗型II型糖尿病患者实时连续血糖监测与自我血糖监测的成本效用比较》的同行评审补充表格。补充表S1：事件/状态的有效性和无效性值。补充表S2：糖尿病并发症或事件的成本。补充表S3：年度治疗和设备成本。补充表S4：rt-CGM与SMBG的糖尿病并发症预测。参考文献：仅在线补充材料的参考文献。研究目的：临床试验和真实世界数据均表明，与自我血糖监测（SMBG）相比，实时连续血糖监测（rt-CGM）可以降低胰岛素治疗型II型糖尿病患者的糖化血红蛋白（HbA1c）水平和低血糖发生频率。本研究旨在探讨使用rt-CGM与SMBG在法国胰岛素治疗型II型糖尿病患者中的长期卫生经济影响。材料与方法：有效性数据来源于一项真实世界研究，该研究显示rt-CGM将HbA1c降低了0.56%（6.1 mmol/mol），而持续SMBG则无此效果。分析采用IQVIA核心糖尿病模型进行。以法国支付者视角，在64.5岁、基线HbA1c为8.3%（67 mmol/mol）的队列中，以终身为时间范围进行评估。设定了147,093欧元的支付意愿阈值，并将未来成本和结果按每年4%的比率进行贴现。结果：分析预测，rt-CGM与SMBG相比，质量调整生命预期为8.50质量调整生命年（QALYs），而SMBG为8.03 QALYs（差异：0.47 QALYs），而总平均终身成本分别为rt-CGM的93,978欧元和SMBG的82,834欧元（差异：11,144欧元）。这导致rt-CGM相对于SMBG的增量成本-效用比（ICUR）为每获得1 QALY增加23,772欧元。结果特别敏感于治疗效果（即HbA1c的变化）、rt-CGM与SMBG的年度价格和生活质量效益、SMBG频率、基线患者年龄和并发症成本的变化。结论：对于法国胰岛素治疗型II型糖尿病患者，使用rt-CGM相对于SMBG可能是成本效益的。